1. Home
  2. LPA vs LUNG Comparison

LPA vs LUNG Comparison

Compare LPA & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LPA

Logistic Properties of the Americas

N/A

Current Price

$2.60

Market Cap

79.0M

Sector

N/A

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.79

Market Cap

72.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LPA
LUNG
Founded
2013
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
72.2M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
LPA
LUNG
Price
$2.60
$1.79
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
10.1K
645.4K
Earning Date
01-01-0001
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
N/A
$83,789,000.00
Revenue This Year
N/A
$6.20
Revenue Next Year
N/A
$21.61
P/E Ratio
$11.25
N/A
Revenue Growth
N/A
22.01
52 Week Low
$2.04
$1.31
52 Week High
$9.81
$8.10

Technical Indicators

Market Signals
Indicator
LPA
LUNG
Relative Strength Index (RSI) 49.98 56.22
Support Level $2.57 $1.44
Resistance Level $2.94 $1.93
Average True Range (ATR) 0.12 0.16
MACD 0.03 0.05
Stochastic Oscillator 72.51 52.00

Price Performance

Historical Comparison
LPA
LUNG

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns, and manages a diversified portfolio of warehouse logistics assets in Central America and South America. It focuses on modern Class A logistics real estate in high-growth and high-barrier-to-entry markets that are undersupplied and have low penetration rates. The company has three operating segments, based on geographic regions, consisting of Colombia, Peru, and Costa Rica. The company generates the majority of its revenue from the Costa Rica geographical segment.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: